Endothelial expression of nonclassic HLA molecules: Functions and potential implication in clinical transplantation

Current Opinion in Organ Transplantation

Volumn 11, Issue 4, 2006, Pages 433-438

  Coupel, Stéphanie ^a   Soulillou, Jean Paul ^a   Charreau, Béatrice ^b  

^a INSERM   (France)

^b ITERT ^*

Author keywords

Activation; Allogeneic response; Endothelial cells; Innate immunity; Natural killer cells and receptors

Indexed keywords

HLA ANTIBODY;

ALLOIMMUNITY; ANTIGEN EXPRESSION; ENDOTHELIUM CELL; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HUMAN; IMMUNOLOGICAL TOLERANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR DYNAMICS; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; XENOGRAFT;

EID: 33746325449     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/01.mot.0000236709.90952.89     Document Type: Review

References (48)

1. Briscoe DM, Sayegh MH. A rendezvous before rejection: where do T cells meet transplant antigens? Nat Med 2002; 8:220-222.
2. Pober J, Orosz CG, Rose ML, Savage CO. Can graft endothelial cells initiate a host antigraft immune response? Transplantation 1996; 61:343-349.
3. Rothermel AL, Wang Y, Schechner J, et al. Endothelial cells present antigens in vivo. BMC Immunol 2004; 5:5.
4. Zwirner NW, Dole K, Stastny P. Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes. Hum Immunol 1999; 60:323-330.
5. Stephens HA. MICA and MICB genes: can the enigma of their polymorphism be resolved? Trends Immunol 2001; 22:378-385.
6. Groh V, Bahram S, Bauer S, et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A 1996; 93:12445-12450.
7. Ogasawara K, Lanier LL. NKG2D in NK and T cell-mediated immunity. J Clin Immunol 2005; 25:534-540.
8. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285:727-729.
9. Cao W, He W. UL16 binding proteins. Immunobiology 2004; 209:283-290.
10. Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002; 169:4098-4102.
11. Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102:1389-1396.
12. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-738.
13. Zwirner NW, Marcos CY, Mirbaha F, et al. Identification of MICA as a new polymorphic alloantigen recognized by antibodies in sera of organ transplant recipients. Hum Immunol 2000; 61:917-924.
14. Sumitran-Holgersson S, Wilczek HE, Holgersson J, Soderstrom K. Identification of the nonclassical HLA molecules, MICA, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 2002; 74:268-277.
15. Hankey KG, Drachenberg CB, Papadimitriou JC, et al. MIC expression in renal and pancreatic allografts. Transplantation 2002; 73:304-306.
16. Kriegeskorte AK, Gebhardt FE, Porcellini S, et al. NKG2D-independent suppression of T cell proliferation by H60 and MICA. Proc Natl Acad Sci U S A 2005; 102:11805-11810. This sudy shows that MICA can also mediate strong suppressive effects on T-cell proliferation. These findings provide a new function for MICA in immune escape.
17. Lila N, Carpentier A, Amrein C, et al. Implication of HLA-G molecule in heart-graft acceptance [letter to the editor]. Lancet 2000; 355:2138.
18. Lila N, Amrein C, Guillemain R, et al. Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation 2002; 105:1949-1954.
19. LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 2005; 19:662-664. This in-vitro study reveals that expression of the inhibitory receptors ILT2, ILT3, ILT4, and KIR2DL4 is upregulated by HLA-G in APCs, natural killer cells, and T cells.
20. Wiendl H, Feger U, Mittelbronn M, et al. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain 2005; 128:2689-2704.
21. Riteau B, Rouas-Freiss N, Menier C, et al. HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol 2001; 166:5018-5026.
22. Bainbridge DR, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J Reprod Immunol 2000; 48:17-26.
23. Lila N, Rouas-Freiss N, Dausset J, et al. Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci U S A 2001; 98:12150-12155.
24. Manavalan JS, Kim-Schulze S, Scotto L, et al. Alloantigen specific CD8+CD28-FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol 2004; 16:1055-1068.
25. Suciu-Foca N, Manavalan JS, Scotto L, et al. Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: review. Int Immunopharmacol 2005; 5:7-11.
26. Kim-Schulze S, Seki T, Vlad G, et al. Regulation of ILT3 gene expression by processing of precursor transcripts in human endothelial cells. Am J Transplant 2006; 6:76-82. This study documented ILT3 mRNA and protein expression in human endothelial cells.
27. Braud VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A. B and C. Nature 1998; 391:795-799.
28. Lee N, Llano M, Carretero M, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A 1998; 95:5199-5204.
29. Braud V, Jones EY, McMichael A. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur J Immunol 1997; 27:1164-1169.
30. Lee N, Goodlett DR, Ishitani A, et al. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol 1998; 160:4951-4960.
31. King A, Allan DS, Bowen M, et al. HLA-E is expressed on trophoblasts and interacts with CD94/NKG2 receptors on decidual NK cells. Eur J Immunol 2000; 30:1623-1631.
32. Menier C, Saez B, Horejsi V, et al. Characterization of monoclonal antibodies recognizing HLA-G or HLA-E new tools to analyze the expression of non-classical HLA class I molecules. Hum Immunol 2003; 64:315-326.
33. Li J, Goldstein I, Glickman-Nir E, et al. Induction of TCR Vbeta-specific CD8+ CTLs by TCR Vbeta-derived peptides bound to HLA-E. J Immunol 2001; 167:3800-3808.
34. Heinzel AS, Grotzke JE, Lines RA, et al. HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ T cells. J Exp Med 2002; 196:1473-1481.
35. Pacasova R, Martinozzi S, Boulouis HJ, et al. Cell-surface expression and alloantigenic function of a human nonclassical class I molecule (HLA-E) in transgenic mice. J Immunol 1999; 162:5190-5196.
36. Romagnani C, Pietra G, Falco M, et al. Identification of HLA-E-specific alloreactive T lymphocytes: a cell subset that undergoes preferential expansion in mixed lymphocyte culture and displays a broad cytolytic activity against allogeneic cells. Proc Natl Acad Sci U S A 2002; 99:11328-11333.
37. Hu D, Ikizawa K, Lu L, et al. Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat Immunol 2004; 5:516-523.
38. Panoutsakopoulou V, Huster KM, McCarty N, et al. Suppression of autoimmune disease after vaccination with autoreactive T cells that express Qa-1 peptide complexes. J Clin Invest 2004; 113:1218-1224.
39. Sarantopoulos S, Lu L, Cantor H. Qa-1 restriction of CD8+ suppressor T cells. J Clin Invest 2004; 114:1218-1221.
40. Strong RK, Holmes MA, Li P, et al. HLA-E allelic variants correlating differential expression, peptide affinities, crystal structures, and thermal stabilities. J Biol Chem 2003; 278:5082-5090.
41. Watier H, Guillaumin JM, Vallee I, et al. Human NK cell-mediated direct and IgG-dependent cytotoxicity against xenogeneic porcine endothelial cells. Transpl Immunol 1996; 4:293-299.
42. Matsunami K, Miyagawa S, Nakai R, et al. The possible use of HLA-G1 and G3 in the inhibition of NK cell-mediated swine endothelial cell lysis. Clin Exp Immunol 2001; 126:165-172.
43. Forte P, Baumann BC, Weiss EH, Seebach JD. HLA-E expression on porcine cells: protection from human NK cytotoxicity depends on peptide loading. Am J Transplant 2005; 5:2085-2093.
44. Forte P, Lilienfeld BG, Baumann BC, Seebach JD. Human NK cytotoxicity against porcine cells is triggered by NKp44 and NKG2D. J Immunol 2005; 175:5463-5470.
45. Shiao SL, McNiff JM, Pober JS. Memory T cells and their costimulators in human allograft injury. J Immunol 2005; 175:4886-4896.
46. Lakkis FG, Sayegh MH. Memory T cells: a hurdle to immunologic tolerance. J Am Soc Nephrol 2003; 14:2402-2410.
47. + regulatory T cells, which can inhibit proliferation of alloreactive T cells both in vitro and in vivo in mice.
48. Beilke JN, Kuhl NR, Van Kaer L, Gill RG. NK cells promote islet allograft tolerance via a perforin-dependent mechanism. Nat Med 2005; 11:1059-1065. The authors propose that innate natural killer and natural killer T cells, which also require host expression of MHC class I molecules, might be involved in allograft tolerance.